View Older Stories View More Recent Stories

Jan 16, 2026 08:46AM Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Jan 16, 2026 08:43AM Cardiol Therapeutics raises $13.5 million in bought deal financing
Jan 16, 2026 08:42AM Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Jan 13, 2026 07:29AM Cardiol Therapeutics reaches 50% enrollment in phase III pericarditis trial
Jan 13, 2026 07:27AM Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Dec 2, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Cardiol Therapeutics (CRDL)
Dec 1, 2025 07:29AM Cardiol reports heart structure improvements in myocarditis trial
Dec 1, 2025 07:27AM New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Nov 13, 2025 07:48AM Cardiol Therapeutics receives U.S. patent allowance for heart drugs through 2040
Nov 13, 2025 07:45AM Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
Nov 5, 2025 07:45AM Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
Oct 21, 2025 07:27AM Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
Oct 17, 2025 04:36PM Cardiol Therapeutics raises $11 million, extends cash runway to Q3 2027
Oct 17, 2025 04:34PM Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027
Sep 17, 2025 03:33PM Brookline Capital Markets Starts Cardiol Therapeutics (CRDL) at Buy, PT $6
Aug 11, 2025 07:27AM Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
Aug 6, 2025 07:27AM Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Jul 23, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Cardiol Therapeutics (CRDL)
Jul 22, 2025 07:30AM Cardiol locks database for phase II myocarditis trial
Jul 22, 2025 07:27AM Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Jun 2, 2025 06:36AM H.C. Wainwright Starts Cardiol Therapeutics (CRDL) at Buy
May 29, 2025 07:27AM Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders
May 27, 2025 07:27AM Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT
Apr 29, 2025 07:29AM Cardiol Therapeutics (CRDL) Nominates Timothy Garnett to Its Board
Apr 29, 2025 07:27AM Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
Apr 16, 2025 07:29AM Cardiol Therapeutics (CRDL) Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Apr 16, 2025 07:27AM Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Apr 8, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Cardiol Therapeutics (CRDL)
Apr 1, 2025 07:29AM Cardiol Therapeutics (CRDL) Issues Year-end Update on Operations
Apr 1, 2025 07:27AM Cardiol Therapeutics Announces Year-End 2024 Update on Operations
Mar 3, 2025 07:27AM Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Feb 20, 2025 07:29AM Cardiol Therapeutics (CRDL) Announces Publication of Research in the Journal of the American College of Cardiology
Feb 20, 2025 07:27AM Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Dr
Feb 4, 2025 07:27AM Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Jan 28, 2025 06:45AM Rodman & Renshaw Starts Cardiol Therapeutics (CRDL) at Buy
Nov 18, 2024 11:37AM Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Oct 24, 2024 07:44AM H.C. Wainwright Reiterates Buy Rating on Cardiol Therapeutics (CRDL)
Oct 22, 2024 06:32AM Cardiol Therapeutics (CRDL) to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis
Oct 22, 2024 06:30AM Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis
Oct 20, 2024 10:00AM 4 biotech stocks to own to benefit from key Q4 catalysts
Oct 11, 2024 08:39AM Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option
Oct 10, 2024 09:09AM Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares
Oct 9, 2024 08:01AM Cardiol Therapeutics (CRDL) Announces Pricing of Public Offering of Common Shares
Oct 9, 2024 07:58AM Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares
Oct 8, 2024 04:03PM Cardiol Therapeutics (CRDL) Files Preliminary Prospectus Supplement for Proposed Share Offering
Oct 8, 2024 04:01PM Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
Sep 25, 2024 06:00AM Roth/MKM Reiterates Buy Rating on Cardiol Therapeutics (CRDL)
Sep 24, 2024 07:27AM Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis
Sep 10, 2024 07:29AM Cardiol Therapeutics (CRDL) Announces Completion of the MAvERIC Phase II Study
Sep 10, 2024 07:27AM Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024
View More Recent Stories View Older Stories